Reaction
Melanoma Recurrent reporting signals
As of the last recalculation, Melanoma Recurrent appears in 414 FAERS reports alongside 7 co-occurring drug terms. The strongest observed disproportionality signal is DABRAFENIB (PRR 157.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Dabrafenib | 57 | 157.6 | 158.0 |
| Trametinib | 54 | 129.1 | 129.3 |
| Vemurafenib | 11 | 47.2 | 47.3 |
| Pembrolizumab | 56 | 30.8 | 30.8 |
| Acalabrutinib | 6 | 25.2 | 25.3 |
| Ipilimumab | 20 | 24.4 | 24.4 |
| Nivolumab | 35 | 19.8 | 19.8 |